Send to

Choose Destination
Oncotarget. 2016 Nov 15;7(46):76006-76020. doi: 10.18632/oncotarget.12579.

Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells.

Author information

Department of Obstetrics and Gynecology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.
Department of Oncology, No. 421 Hospital of PLA, Guangzhou 510318, China.
Department of Oncology, Fuzhou General Hospital, Fuzhou, Fujian 350025, China.


Cancer stem cells (CSCs) are a group of cells which possess the ability of self-renewing and unlimited proliferation. And these CSCs are thought to be the cause of metastasis, recurrence and resistance. Recent study has found that pro-inflammatory cytokine and chemotactic factor mediate the self-renewing and differentiation of most of CSCs. Thus we speculate that ovarian cancer stem cells (OCSCs) can also maintain the ability of self-renewing and differentiation by releasing inflammatory factor. This report we discuss the biological characteristics and the specific molecular mechanism mediated by interleukin-23 (IL-23) and its receptor on the self-renewing of OCSCs. We found that OCSCs had high expression of IL-23 and IL-23R. IL-23 could promote the self-renewal ability of OCSCs and played a very important role to maintain the stable expression of stem cell markers in vitro. Moreover, we verified that IL-23 could maintain the potential tumorigenic of OCSCs in vivo and mediate the self-renewal ability and the formation of tumor in OCSCs by activating the signal pathways of STAT3 and NF-κB. In addition, human low differentiation tissues showed overexpression of IL-23. And IL-23 positively correlated to the expression level of CD133, Nanog and Oct4. In conclusion, Our discoveries demonstrate that autocrine IL-23 contribute to ovarian cancer malignancy through promoting the self-renewal of CD133+ ovarian cancer stem-like cells, and this suggests that IL-23 and its signaling pathway might serve as therapeutic targets for the treatment of ovarian cancer.


IL-23; cancer stem cells; ovarian cancer; self-renewal

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center